3
Announcements
Trials
Browse
Landscape
Status
Completed
2
Sponsor Class
OTHER
19
INDUSTRY
2
NETWORK
1
Study Type
Interventional
29
Observational
2
Sponsor
Conditions
Breast Neoplasms
467
Neoplasms
315
Carcinoma, Non-Small-Cell Lung
269
Prostatic Neoplasms
215
Colorectal Neoplasms
207
Lung Neoplasms
176
Multiple Myeloma
123
Melanoma
110
Carcinoma, Renal Cell
107
Ovarian Neoplasms
94
Carcinoma, Hepatocellular
78
Pancreatic Neoplasms
69
Urinary Bladder Neoplasms
65
Stomach Neoplasms
64
Neoplasm Metastasis
64
Leukemia, Lymphocytic, Chronic, B-Cell
62
Colonic Neoplasms
59
Leukemia, Myeloid, Acute
53
Uterine Cervical Neoplasms
50
Recurrence
49
Liver Neoplasms
46
Lymphoma, Follicular
45
Lymphoma
45
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
39
Esophageal Neoplasms
37
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Lymphoma, Large B-Cell, Diffuse
35
Hematologic Neoplasms
35
Head and Neck Neoplasms
35
Lymphoma, Non-Hodgkin
34
Interventions
netupitant, palosentron drug combination
1
NDC80 protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Observational
×
Vomiting
×
Clear all
NCT03649230
2023-08-18
EVOLVE_CINV
Purdue Pharma, Canada
Completed
207 enrolled
10 charts
NCT01366599
2017-05-24
CV Events in Emetogenic Chemotherapy
GlaxoSmithKline
Completed
12,058 enrolled